$40 Billion Per Year for COVID Vaccine Makers Hinges on This 1 Unanswered Question
Let the money roll in. That's what shareholders of Pfizer (NYSE: PFE), BioNTech (NASDAQ: BNTX), and Moderna (NASDAQ: MRNA) could be thinking right now.
The U.S. Food and Drug Administration granted Emergency Use Authorization (EUA) to Pfizer's and BioNTech's coronavirus vaccine BNT162b2 a little over a week ago. Moderna won EUA for its COVID-19 vaccine mRNA-1273 this past week after a positive recommendation from an FDA advisory panel. All three drugmakers stand to make a lot of money from supply agreements that they've already signed.
Bernstein analyst Ronny Gal predicts that the market for COVID-19 vaccines will approach $40 billion in 2021. But will companies continue to split a market that big in subsequent years? It all hinges on one unanswered question.
Source Fool.com
